Pharmacological treatment strategies in acute schizophrenia

International Clinical Psychopharmacology

Volumn 11, Issue SUPPL. 2, 1996, Pages 29-34

  Marder, S R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antipsychotic; Clozapine; Olanzapine; Risperidone; Schizophrenia; Seroquel; Sertindole

Indexed keywords

BENZODIAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; TRIFLUOPERAZINE;

CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0029886133     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199605002-00005     Document Type: Conference Paper

References (24)

1. Altamura AC, Mauri MC, Mantero M, Brunetti M (1987) Clonazepam/haloperidol combination therapy in schizophrenia: a double-blind study. Acta Psychiatr Scand 76:702-706.
2. Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79-90.
3. Braude WM, Barnes TR, Gore SM (1983) Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 143:139-50.
4. Bondolfi G, Bauman P, Patris M, et al. (1995) A randomized double-blind trial of risperidone versus clozapine for treatment resistant chronic schizophrenia. In 1995 Annual Meeting New Research Program and Abstracts. Washington, DC: American Psychiatric Association; p 185.
5. Janicak PG, Davis JM, Preskorn SH, Ayd FJ (1993) Principles and Practice of Psychopharmacology. Baltimore: Williams and Wilkins; pp 93-184.
6. Kahn RS, Davis KL (1995) New developments in dopamine and schizophrenia. In Psychopharamcology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York: Raven Press; pp 1193-1203.
7. Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 45:789-796.
8. Kinon BJ, Kane JM, Johns C, et al. (1993) Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 29:309-314.
9. Levinson DF, Simpson GM, Sing H, et al. (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 47:726-729.
10. Marder SR, Davis JM, Janicak PG (1993) Use and interpretation of neuroleptic drug plasma levels. In Clinical Use of Neuroleptic Plasma Levels. Edited by Marder SR, Davis JM, Janicak PG. Washington, DC: Amercan Psychiatric Press; pp 137-142.
11. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
12. Miller DD, Fleming F, Holman TL, et al. (1994) Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 55 (suppl B):117-121.
13. Neborsky R, Janowsky D, Munson E, Depry D (1981) Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol: behavioral considerations. Arch Gen Psychiatry 38:195-199.
14. Rifkin A, Doddi S, Karagi B, et al. (1991) Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48:166-170.
15. Salzman C, Green AI, Rodriguez-Villa F, Jaskiw G (1986) Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics 27 (suppl):17-23.
16. Schooler NR, Keith SJ (1993) The clinical research base for the treatment of schizophrenia. In Health Care Reform for Americans with Severe Mental Illnesses: Report of the National Advisory Mental Health Council, Department of Health and Human Services. Washington, DC: Government Printing Office; 2-30.
17. Scott JE, Dixon LB (1995) Psychological interventions for schizophrenia. Schizophr Bull 4:621-630.
18. Thompson C (1994) The use of high-dose antipsychotic medication. Br J Psychiatry 164:448-458.
19. Van Putten T, Marder SR (1987) Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 48 (suppl):13-19.
20. Van Putten T, Marder SR, Mintz J (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 47:754-758.
21. Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N (1991) Neuroleptic plasma levels. Schizophr Bull 17:197-216.
22. Van Putten T, May PRA, Marder SR (1984) Response to antipsychotic medication: the doctor's and the consumer's view. Am J Psychiatry 141:16-19.
23. Volavka J, Cooper T, Czobor P, et al. (1992) Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49:354-361.
24. Wyatt RJ (1991) Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17:325-351.